Patient engagement becomes the new normal in drug development

05/9/2013 | Genetic Engineering & Biotechnology News

Drugmaker Raptor's willingness to interact with patients and advocacy groups led to the creation of newly approved Procysbi to treat the rare kidney disease nephropathic cystinosis. Other drugmakers are following Raptor's lead to stay competitive and shift focus from regulatory approval to value for patients, says National Health Council executive vice president Marc Boutin. "It really requires a cultural shift within the researchers and within the organizations," Boutin said. "And it requires that multiple silos within any pharmaceutical company have to come together and figure out what is that strategy going to be."

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC